Harmony BioSciences’ shares fall following critical short-seller report


A short-seller raised questions about the company's narcolepsy drug; Harmony "disagrees with their assertions."

Previous Program from Secret wants to help Gen Z, millennial women stop sweating their finances
Next Onix Group plans new $90M building with hotel, conference center, medical offices and more near AdventHealth Orlando